Virtual Library
Start Your Search
P. Hass
Author of
-
+
P2.05 - Poster Session with Presenters Present (ID 463)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Radiotherapy
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.05-044 - Influence of Technological Advances and Institutional Experience on Outcome of Stereotactic Body Radiotherapy for Lung Metastases (ID 5675)
14:30 - 14:30 | Author(s): P. Hass
- Abstract
Background:
Many technological and methodical advances have made stereotactic body radiotherapy (SBRT) more accurate and more efficient during the last years. This study aims to investigate whether technological innovations and experience in SBRT also translated into improved local control (LC) and overall survival (OS).
Methods:
The working group “Stereotactic Radiotherapy” of the German Society for Radiation Oncology established a database of 700 patients treated with SBRT for lung metastases in 20 German centers between 1997 and 2014. It was the aim of this study to analyze the impact of FDG-PET staging (fluoro-deoxy-glucose positron emission tomography), biopsy confirmation, image guidance, immobilization and dose calculation algorithm as well as the influence of SBRT treatment experience on LC and OS.
Results:
Median follow-up time was 14.3 months (range 0-131.9 months) with 2-year LC and OS of 81.2% and 54.4%, respectively. In multivariate analysis, all treatment technologies except FDG-PET staging did not significantly influence outcome. Patients who received pre-SBRT FDG-PET staging showed superior 1- and 2-year OS of 82.7% and 64.8% compared to patients without FDG-PET staging resulting in 1- and 2-year OS rates of 72.8% and 52.6%, respectively (p=0.012). SBRT treatment experience was identified as the main prognostic factor for local control: institutions with higher SBRT experience (patients treated with SBRT within the last 24 months) showed superior LC compared to less experienced centers (p≤0.001). SBRT treatment experience within the last 24 months was independent from known prognostic factors for LC.
Conclusion:
Technological and methodical advancements except FDG-PET staging prior to SBRT did not significantly improve outcome in SBRT for pulmonary metastases. On the contrary, LC was superior with increasing SBRT treatment experience of the individual center.
